SHMT2 and colorectal carcinoma: Taken together, our studies provide evidence that cytoplasmic SHMT2 plays an important role in promoting CRC progression by inhibiting the degradation of β-catenin, implicating SHMT2 as both a potential therapeutic target and a predictor of survival in CRC.